RT Journal Article
SR Electronic
T1 Detection of SARS-CoV-2 infection by saliva and nasopharyngeal sampling in frontline healthcare workers: an observational cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.23.21255964
DO 10.1101/2021.04.23.21255964
A1 Naomi F. Walker
A1 Rachel L. Byrne
A1 Ashleigh Howard
A1 Elissavet Nikolaou
A1 Madlen Farrar
A1 Sharon Glynn
A1 Katerina S. Cheliotis
A1 Ana I. Cubas Atienzar
A1 Kelly Davies
A1 Jesus Reine
A1 Zalina Rashid-Gardner
A1 Esther L. German
A1 Carla Solórzano
A1 Tess Blandamer
A1 Lisa Hitchins
A1 Christopher Myerscough
A1 Brad Gessner
A1 Elizabeth Biegner
A1 Andrea M. Collins
A1 Mike Beadsworth
A1 Stacy Todd
A1 Helen Hill
A1 Catherine F. Houlihan
A1 Eleni Nastouli
A1 on behalf of the SAFER investigators
A1 Emily R. Adams
A1 Elena Mitsi
A1 Daniela M. Ferreira
YR 2021
UL http://medrxiv.org/content/early/2021/04/26/2021.04.23.21255964.abstract
AB Background The SARS-CoV-2 pandemic has caused an unprecedented strain on healthcare systems worldwide, including the UK National Health Service (NHS). During the first wave of SARS-CoV-2 transmission in UK, SARS-CoV-2 NHS diagnostic test availability was limited to self-isolating symptomatic staff. The burden of symptomatic and asymptomatic infection in healthcare workers (HCW) attending work was unknown.Methods We conducted an observational cohort study of SARS-CoV-2 infection in HCW working in an acute NHS Trust during the first wave of the COVID-19 pandemic, using serial self-collected saliva and nasopharyngeal (NP) samples. We also collected self-assessed symptom profiles and isolation behaviours. We retrospectively compared SARS-CoV-2 detection by RT-PCR from saliva (weekly) and NP swabs (twice weekly) from 85 individuals in this cohort and evaluated the association with symptoms.Findings Over a 12-week period from 30th March 2020, 40% (n=34/85, CI95% 31.3-51.8%) HCWs had evidence of SARS-CoV-2 infection by surveillance NP swab and/or saliva RT-qPCR. Agreement between paired saliva and NP swabs was poor (28.6%, CI95% 13.2-48.7%) with both methods detecting symptomatic and asymptomatic infections. Symptoms were reported by 47.1% (n=40) and self-isolation by 25.9% participants (n=22). Only 41.2% (n=14/34) participants with SARS-CoV-2 infection reported any symptoms within 14 days of the infection.Interpretation HCWs are a potential source of SARS-CoV-2 transmission in hospitals and symptom screening will identify the minority of infections in HCW. Saliva is an easily accessible fluid sample for screening for SARS-CoV-2 infection and in addition to NP swab, facilitated ascertainment of symptomatic and asymptomatic cases in this setting. Combined saliva and NP testing would improve detection of SARS-CoV-2 for surveillance. Better understanding of transmissibility from asymptomatic staff using transmission-based infection precautions, is required to inform policy.Competing Interest StatementThe authors have declared no competing interest.Clinical Trial20/SC/0147Funding StatementLiverpool COVID-19 Partnership Strategic Research Fund to NFW; Pfizer award to DF and EM (grant number WI2558862-1). The Medical Research Council doctoral training partnership fund to RLB. CFH and EN received funding from MRC/UKRI (SAFER study; grant number MC PC 19082)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NHS health research authority (ref 20/SC/0147)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request.